ProfileGDS5678 / 1434325_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 72% 71% 75% 69% 76% 75% 70% 72% 69% 71% 75% 73% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7250373
GSM967853U87-EV human glioblastoma xenograft - Control 24.5820172
GSM967854U87-EV human glioblastoma xenograft - Control 34.5287371
GSM967855U87-EV human glioblastoma xenograft - Control 45.0437175
GSM967856U87-EV human glioblastoma xenograft - Control 54.240569
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9437776
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8673375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3162370
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5658572
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2691869
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.451871
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0084675
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6399773
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9406766